216 related articles for article (PubMed ID: 31680043)
21. Unravelling druggable signalling networks that control F508del-CFTR proteostasis.
Hegde RN; Parashuraman S; Iorio F; Ciciriello F; Capuani F; Carissimo A; Carrella D; Belcastro V; Subramanian A; Bounti L; Persico M; Carlile G; Galietta L; Thomas DY; Di Bernardo D; Luini A
Elife; 2015 Dec; 4():. PubMed ID: 26701908
[TBL] [Abstract][Full Text] [Related]
22. Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease.
Strub MD; McCray PB
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32414011
[TBL] [Abstract][Full Text] [Related]
23. Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation.
Pissarra LS; Farinha CM; Xu Z; Schmidt A; Thibodeau PH; Cai Z; Thomas PJ; Sheppard DN; Amaral MD
Chem Biol; 2008 Jan; 15(1):62-9. PubMed ID: 18215773
[TBL] [Abstract][Full Text] [Related]
24. Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
Lin S; Sui J; Cotard S; Fung B; Andersen J; Zhu P; El Messadi N; Lehar J; Lee M; Staunton J
Assay Drug Dev Technol; 2010 Dec; 8(6):669-84. PubMed ID: 21050065
[TBL] [Abstract][Full Text] [Related]
25. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells.
Favia M; Mancini MT; Bezzerri V; Guerra L; Laselva O; Abbattiscianni AC; Debellis L; Reshkin SJ; Gambari R; Cabrini G; Casavola V
Am J Physiol Lung Cell Mol Physiol; 2014 Jul; 307(1):L48-61. PubMed ID: 24816489
[TBL] [Abstract][Full Text] [Related]
26. Silencing of the Hsp70-specific nucleotide-exchange factor BAG3 corrects the F508del-CFTR variant by restoring autophagy.
Hutt DM; Mishra SK; Roth DM; Larsen MB; Angles F; Frizzell RA; Balch WE
J Biol Chem; 2018 Aug; 293(35):13682-13695. PubMed ID: 29986884
[TBL] [Abstract][Full Text] [Related]
27. Macromolecular interactions and ion transport in cystic fibrosis.
Guggino WB; Banks-Schlegel SP
Am J Respir Crit Care Med; 2004 Oct; 170(7):815-20. PubMed ID: 15447951
[TBL] [Abstract][Full Text] [Related]
28. CFTR Folding: From Structure and Proteostasis to Cystic Fibrosis Personalized Medicine.
McDonald EF; Meiler J; Plate L
ACS Chem Biol; 2023 Oct; 18(10):2128-2143. PubMed ID: 37730207
[TBL] [Abstract][Full Text] [Related]
29. Targeting Molecular Chaperones for the Treatment of Cystic Fibrosis: Is It a Viable Approach?
Heard A; Thompson J; Carver J; Bakey M; Wang XR
Curr Drug Targets; 2015; 16(9):958-64. PubMed ID: 25981601
[TBL] [Abstract][Full Text] [Related]
30. Full Rescue of F508del-CFTR Processing and Function by CFTR Modulators Can Be Achieved by Removal of Two Regulatory Regions.
Uliyakina I; Botelho HM; da Paula AC; Afonso S; Lobo MJ; Felício V; Farinha CM; Amaral MD
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630527
[TBL] [Abstract][Full Text] [Related]
31. SUMOylation Inhibition Enhances Protein Transcription under CMV Promoter: A Lesson from a Study with the F508del-CFTR Mutant.
Borgo C; D'Amore C; Capurro V; Tomati V; Pedemonte N; Bosello Travain V; Salvi M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396982
[TBL] [Abstract][Full Text] [Related]
32. Can correcting the ΔF508-CFTR proteostasis-defect rescue CF lung disease?
Valle CW; Vij N
Curr Mol Med; 2012 Aug; 12(7):860-71. PubMed ID: 22697346
[TBL] [Abstract][Full Text] [Related]
33. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.
Amaral MD
Curr Drug Targets; 2011 May; 12(5):683-93. PubMed ID: 21039334
[TBL] [Abstract][Full Text] [Related]
34. Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation.
De Stefano D; Villella VR; Esposito S; Tosco A; Sepe A; De Gregorio F; Salvadori L; Grassia R; Leone CA; De Rosa G; Maiuri MC; Pettoello-Mantovani M; Guido S; Bossi A; Zolin A; Venerando A; Pinna LA; Mehta A; Bona G; Kroemer G; Maiuri L; Raia V
Autophagy; 2014; 10(11):2053-74. PubMed ID: 25350163
[TBL] [Abstract][Full Text] [Related]
35. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR.
Bose SJ; Bijvelds MJC; Wang Y; Liu J; Cai Z; Bot AGM; de Jonge HR; Sheppard DN
Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L71-L86. PubMed ID: 30969810
[TBL] [Abstract][Full Text] [Related]
36. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Cuyx S; De Boeck K
Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.
Lopes-Pacheco M; Silva IAL; Turner MJ; Carlile GW; Sondo E; Thomas DY; Pedemonte N; Hanrahan JW; Amaral MD
Biochem Pharmacol; 2020 Oct; 180():114133. PubMed ID: 32628927
[TBL] [Abstract][Full Text] [Related]
38. Impact of the F508del mutation on ovine CFTR, a Cl- channel with enhanced conductance and ATP-dependent gating.
Cai Z; Palmai-Pallag T; Khuituan P; Mutolo MJ; Boinot C; Liu B; Scott-Ward TS; Callebaut I; Harris A; Sheppard DN
J Physiol; 2015 Jun; 593(11):2427-46. PubMed ID: 25763566
[TBL] [Abstract][Full Text] [Related]
39. CFTR: folding, misfolding and correcting the ΔF508 conformational defect.
Lukacs GL; Verkman AS
Trends Mol Med; 2012 Feb; 18(2):81-91. PubMed ID: 22138491
[TBL] [Abstract][Full Text] [Related]
40. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
Bell SC; De Boeck K; Amaral MD
Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
